National Institute of Allergy and Infectious Diseases; Notice of Closed Meeting, 50380 [05-17018]

Download as PDF 50380 Federal Register / Vol. 70, No. 165 / Friday, August 26, 2005 / Notices would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: National Institute of Environmental Health Sciences Special Emphasis Panel Review of Research Program Projects (P01s). Date: September 27, 2005. Time: 8 a.m. to 5 p.m. Agenda: To review and evaluate grant applications. Place: Hawthorne Suites Hotel, 300 Meredith Drive, Research Triangle Park, NC 27713. Contact Person: Janice B. Allen, PhD, Scientific Review Administrator, Scientific Review Branch, Division of Extramural Research and Training, Nat. Institute of Environmental Health Science, P.O. Box 12233, MD EC–30/Room 3170B, Research Triangle Park, NC 27709, (919) 541–7556. (Catalogue of Federal Domestic Assistance Program Nos. 93.115, Biometry and Risk Estimation—Health Risks from Environmental Exposures; 93.142, NIEHS Hazardous Waste Worker Health and Safety Training; 93.143, NIEHS Superfund Hazardous Substances—Basic Research and Education; 93.894, Resources and Manpower Development in the Environmental Health Sciences; 93.113, Biological Response to Environmental Health Hazards; 93.114, Applied Toxicological Research and Testing, National Institutes of Health, HHS) Dated: August 17, 2005. Anthony M. Coelho, Jr., Acting Director, Office of Federal Advisory Committee Policy. [FR Doc. 05–17014 Filed 8–25–05; 8:45 am] BILLING CODE 4140–01–M DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Institute of Allergy and Infectious Diseases; Notice of Closed Meeting Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meeting. The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: National Institute of Allergy and Infectious Diseases Special Emphasis Panel Review of an Unsolicited VerDate jul<14>2003 16:18 Aug 25, 2005 Jkt 205001 Revised Tyrosine Phosphatase Program Project Application Date: September 20, 2005. Time: 10 a.m. to 1 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, Rockledge 6700, 6700B Rockledge Drive, 3118, Bethesda, MD 20817. (Telephone Conference Call.) Contact Person: Quirijn Vos, PhD, Scientific Review Administrator, Scientific Review Program, Division of Extramural Activities, NIAID/NIH/DHHS, 6700B Rockledge Drive, MSC 7616, Bethesda, MD 20892–7616, (301) 496–2550 qvos@niaid.nih.gov. (Catalogue of Federal Domestic Assistance Program Nos. 93.855, Allergy, Immunology, and Transplantation Research; 93.856, Microbiology and Infectious Diseases Research, National Institutes of Health, HHS) Dated: August 19, 2005. Anthony M. Coelho, Jr., Acting Director, Office of Federal Advisory Committee Policy. [FR Doc. 05–17018 Filed 8–25–05; 8:45 am] BILLING CODE 4140–01–M DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health Notice of Listing of Members of the National Institutes of Health’s Senior Executive Service Performance Review Board (PRB) The National Institutes of Health (NIH) announces the persons who will serve on the National Institutes of Health’s Senior Executive Service Performance Review Board. This action is being taken in accordance with Title 5, U.S.C., 4314(c)(4), which requires that members of performance review board be appointed in a manner to ensure consistency, stability, and objectivity in performance appraisals, and requires that notice of the appointment of an individual to serve as a member be published in the Federal Register. The following persons will serve on the NIH Performance Review Board, which oversees the evaluation of performance appraisals of NIH Senior Executive Service (SES) members: Ms. Colleen Barros (Chair), Dr. Norka Ruiz Bravo, Dr. Michael Gottesman, Ms. Lynn Hellinger, Dr. Barry Hoffer, Dr. Sharon Hrynkow, Dr. Betsy Humphreys, Dr. Raynard Kington, Dr. Lore Anne McNicol, Dr. Marcelle MorrisonBogorad, Ms. Martha Pine, and Dr. Brent Stanfield. For further information about the NIH Performance Review Board, contact the Office of Human Resources, Workforce Relations Division, National Institutes of PO 00000 Frm 00090 Fmt 4703 Sfmt 4703 Health, Building 31/B3C07, Bethesda, Maryland 20892, telephone (301) 402– 9203 (not a toll-free number). Dated: August 16, 2005. Elias A. Zerhouni, Director, National Institutes of Health. [FR Doc. 05–17019 Filed 8–25–05; 8:45 am] BILLING CODE 4140–01–M DEPARTMENT OF HEALTH AND HUMAN SERVICES Substance Abuse and Mental Health Services Administration Agency Information Collection Activities: Submission for OMB Review; Comment Request Periodically, the Substance Abuse and Mental Health Services Administration (SAMHSA) will publish a summary of information collection requests under OMB review, in compliance with the Paperwork Reduction Act (44 U.S.C. Chapter 35). To request a copy of these documents, call the SAMHSA Reports Clearance Officer on (240) 276–1243. Drug and Alcohol Services Information System (DASIS) (OMB No. 0930– 0106)—Revision The DASIS consists of three related data systems: The Inventory of Substance Abuse Treatment Services (I– SATS); the National Survey of Substance Abuse Treatment Services (N–SSATS), and the Treatment Episode Data Set (TEDS). The I–SATS includes all substance abuse treatment facilities known to SAMHSA. The N–SSATS is an annual survey of all substance abuse treatment facilities listed in the I–SATS. The TEDS is a compilation of clientlevel admission data and discharge data submitted by States on clients treated in facilities that receive State funds. Together, the three DASIS components provide information on the location, scope and characteristics of all known drug and alcohol treatment facilities in the United States, the number of persons in treatment, and the characteristics of clients receiving services at publicly-funded facilities. This information is needed to assess the nature and extent of these resources, to identify gaps in services, to provide a database for treatment referrals, and to assess demographic and substancerelated trends in treatment. In addition, SAMHSA and the State substance abuse officials participating in SAMHSA’s December 2004 meeting on National Outcome Measures (NOMS) agreed that several NOMS data elements to assess the performance of the Substance Abuse E:\FR\FM\26AUN1.SGM 26AUN1

Agencies

[Federal Register Volume 70, Number 165 (Friday, August 26, 2005)]
[Notices]
[Page 50380]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 05-17018]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


National Institute of Allergy and Infectious Diseases; Notice of 
Closed Meeting

    Pursuant to section 10(d) of the Federal Advisory Committee Act, as 
amended (5 U.S.C. Appendix 2), notice is hereby given of the following 
meeting.
    The meeting will be closed to the public in accordance with the 
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 
U.S.C., as amended. The grant applications and the discussions could 
disclose confidential trade secrets or commercial property such as 
patentable material, and personal information concerning individuals 
associated with the grant applications, the disclosure of which would 
constitute a clearly unwarranted invasion of personal privacy.

    Name of Committee: National Institute of Allergy and Infectious 
Diseases Special Emphasis Panel Review of an Unsolicited Revised 
Tyrosine Phosphatase Program Project Application
    Date: September 20, 2005.
    Time: 10 a.m. to 1 p.m.
    Agenda: To review and evaluate grant applications.
    Place: National Institutes of Health, Rockledge 6700, 6700B 
Rockledge Drive, 3118, Bethesda, MD 20817. (Telephone Conference 
Call.)
    Contact Person: Quirijn Vos, PhD, Scientific Review 
Administrator, Scientific Review Program, Division of Extramural 
Activities, NIAID/NIH/DHHS, 6700B Rockledge Drive, MSC 7616, 
Bethesda, MD 20892-7616, (301) 496-2550 qvos@niaid.nih.gov.

(Catalogue of Federal Domestic Assistance Program Nos. 93.855, 
Allergy, Immunology, and Transplantation Research; 93.856, 
Microbiology and Infectious Diseases Research, National Institutes 
of Health, HHS)

    Dated: August 19, 2005.
Anthony M. Coelho, Jr.,
Acting Director, Office of Federal Advisory Committee Policy.
[FR Doc. 05-17018 Filed 8-25-05; 8:45 am]
BILLING CODE 4140-01-M
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.